Results 41 to 50 of about 2,872,365 (306)

Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada

Preventive medicine reports, 2023
Highlights • There was a 56.6% decline in overall opioid agonist therapy (OAT) retention among people with HIV (PWH) between 2008 and 2020.• Buprenorphine/naloxone was associated with reduced odds of retention.• Conversely, the odds of retention in slow ...
Kiana Yazdani, Katerina Dolguikh, Monica Ye, J. Trigg, R. Joe, S. D. Emerson, J. Montaner, R. Barrios, K. Salters   +8 more
semanticscholar   +1 more source

Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic

Journal of addiction medicine, 2023
Objectives The primary objectives of this study were to describe the demographics and clinical characteristics of patients who were treated with buprenorphine extended-release versus buprenorphine-naloxone sublingual tablets versus methadone in a real ...
Kenneth Y. Lee, Yue Zhao, T. Merali, C. Fraser, J. Kozicky, M. Mormont, B. Conway   +6 more
semanticscholar   +1 more source

Substances used and OAT (Opioid agonist therapy).

, 2022
Substances used and OAT (Opioid agonist therapy).
Mitchell Levine (445928), Sarah van Gaalen (12436936), Dale Kalina (12436933), Aidan Reid Findlater (12436939), Mark Loeb (248712), Elizabeth Alvarez (4908070), Marek Smieja (117473), Sureka Pavalagantharajah (12436924), Anna Cvetkovic (10670541), Jacqueline Lim (4238824), Eric Lentz (12436930), Lawrence Mbuagbaw (117465), Carol Bassim (12436942), Cynthia Lokker (3813832), Jean-Eric Tarride (201689), Tim O’Shea (8283081), Chris P Verschoor (12436927), Robin Lennox (8314125)   +17 more
core   +1 more source

The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder [PDF]

Psychiatric Services, 2019
The study examined whether the use of opioid agonist therapy (OAT) for treatment of opioid use disorder in specialty substance use treatment settings increased following Medicaid expansion.Administrative data on 943,430 admissions from the Treatment Episodes Data Set-Admissions (2010-2016) were used to examine the association between Medicaid expansion
Ramin, Mojtabai, Christine, Mauro, Melanie M, Wall, Colleen L, Barry, Mark, Olfson   +4 more
openaire   +2 more sources

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review

Substance Abuse Treatment, Prevention, and Policy, 2022
Background People living in rural and remote communities in Canada are often disproportionately impacted by opioid use disorder. When compared to urban centres, rural and remote populations face additional barriers to treatment, including geographical ...
Em M. Pijl, Abeer A. Alraja, Elsie Duff, Carol Cooke, Stephen Dash, Nichole Nayak, J. Lamoureux, Ginette Poulin, Erin Knight, B. Fry   +9 more
semanticscholar   +1 more source

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis

The International journal on drug policy, 2022
Background In March 2020, the Ontario government declared a state of emergency due to the growing risk of COVID-19. In response, new guidance for the management of opioid agonist therapy (OAT) was released, which included the expansion of eligibility for
S. Kitchen, Tonya J. Campbell, Siyu Men, N. Bozinoff, Mina Tadrous, T. Antoniou, Jennifer Wyman, D. Werb, C. Munro, T. Gomes   +9 more
semanticscholar   +1 more source

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report

Journal of Addiction Medicine, 2022
Background Injectable opioid agonist therapy (iOAT) is the highest-intensity treatment currently available in Canada for individuals with severe opioid use disorder. However, there is limited data on iOAT administration in the perinatal period, with no research, practice guidelines, or known reports of breastfeeding on iOAT ...
Patricelli, Charissa J., Gouin, Isabelle J., Gordon, Shanlea, Carter, Nicole, Albert, Arianne, Paquette, Vanessa, Stewart, Karly, George, Shawn, Urbanoski, Karen   +8 more
openaire   +2 more sources

Exploring the role of urine drug screening in opioid agonist therapy. [PDF]

Med J Aust
FitzGerald G, Crawford S, Dunlop AJ, Cook J, Membrey D, MacCartney P, Naren T.   +6 more
europepmc   +3 more sources

Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial

Alimentary Pharmacology and Therapeutics, 2022
Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HCV) infection. This international study evaluated point‐of‐care (PoC) HCV RNA diagnostic outreach and direct‐acting antiviral (DAA) treatment for individuals receiving
C. Byrne, A. Radley, S. Inglis, Lewis Beer, Nicki Palmer, Minh Duc Pham, K. Allardice, Huan Wang, E. Robinson, M. Hermansson, Dimitri Semizarov, B. Healy, J. Doyle, J. Dillon   +13 more
semanticscholar   +1 more source

Benefits people experiencing opioid use disorder derive from opioid agonist therapies [PDF]

, 2021
Opioid use disorder has become an epidemic over the past 20 years. Contamination of the street sourced drug supply with fentanyl and fentanyl analogues has resulted in a substantial increase in the associated overdose rate.

core   +1 more source